Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Assets Average (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Assets Average for 10 consecutive years, with $370.4 million as the latest value for Q4 2025.

  • Quarterly Assets Average rose 73.14% to $370.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $370.4 million through Dec 2025, up 73.14% year-over-year, with the annual reading at $298.6 million for FY2025, 29.17% up from the prior year.
  • Assets Average for Q4 2025 was $370.4 million at Akebia Therapeutics, up from $354.9 million in the prior quarter.
  • The five-year high for Assets Average was $636.4 million in Q1 2021, with the low at $213.7 million in Q3 2024.
  • Average Assets Average over 5 years is $383.0 million, with a median of $341.4 million recorded in 2025.
  • The sharpest move saw Assets Average plummeted 50.11% in 2023, then soared 73.14% in 2025.
  • Over 5 years, Assets Average stood at $565.8 million in 2021, then decreased by 29.28% to $400.2 million in 2022, then tumbled by 40.44% to $238.4 million in 2023, then decreased by 10.26% to $213.9 million in 2024, then skyrocketed by 73.14% to $370.4 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $370.4 million, $354.9 million, and $327.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.